Elite 50% OFF Act now – get top investing tools Register Now!

Intellia Therapeutics, Inc.

Contributing Author

Recent Articles by Intellia Therapeutics, Inc.

Nov-10	Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy NTLA GlobeNewswire
Nov-08	Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema NTLA GlobeNewswire
Nov-06	Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates NTLA GlobeNewswire
Oct-27	Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) NTLA GlobeNewswire
Oct-03	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NTLA GlobeNewswire
Sep-25	Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy NTLA GlobeNewswire
Sep-22	Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy NTLA GlobeNewswire
Sep-18	Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema NTLA GlobeNewswire
Aug-07	Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress NTLA GlobeNewswire
Aug-01	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) NTLA GlobeNewswire
Jul-31	Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates NTLA GlobeNewswire
Jul-07	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) NTLA GlobeNewswire
Jun-15	Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress NTLA GlobeNewswire
Jun-05	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) NTLA GlobeNewswire
May-18	Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting NTLA GlobeNewswire
May-08	Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress NTLA GlobeNewswire
May-06	Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) NTLA GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.